Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Wen-Ting Cheng, Hsiu-O Ho, Shyr-Yi Lin, Der-Zen Liu, Ling-Chun Chen & Ming-Thau Sheu. (2021) Carfilzomib and Paclitaxel Co-Loaded Protein Nanoparticles an Effective Therapy Against Pancreatic Adenocarcinomas. International Journal of Nanomedicine 16, pages 6825-6841.
Read now
Read now
Nasimudeen R. Jabir, Khalid Anwar, Chelapram K. Firoz, Mohammad Oves, Mohammad Amjad Kamal & Shams Tabrez. (2018) An overview on the current status of cancer nanomedicines. Current Medical Research and Opinion 34:5, pages 911-921.
Read now
Read now
Bao Ngoc Tran, Hanh Thuy Nguyen, Jong Oh Kim, Chul Soon Yong & Chien Ngoc Nguyen. (2017) Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response. Drug Development and Industrial Pharmacy 43:12, pages 1952-1962.
Read now
Read now
Kazutoshi Komiya, Tomomi Nakamura, Chiho Nakashima, Koichiro Takahashi, Hitomi Umeguchi, Naomi Watanabe, Akemi Sato, Yuji Takeda, Shinya Kimura & Naoko Sueoka-Aragane. (2016) SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer. OncoTargets and Therapy 9, pages 6663-6668.
Read now
Read now
Cristiano Ferrario & Gerald Batist. (2014) Advances in the approach to novel drug clinical development for breast cancer. Expert Opinion on Drug Discovery 9:6, pages 647-668.
Read now
Read now
Articles from other publishers (58)
Ashish Singh, Josh Thomas Georgy, Sakthi Dhananjayan, Elanthenral Sigamani, Ajoy Oommen John, Anjana Joel, Jagan Chandramohan, Rajadurai Abarna, Grace Rebekah, Selvamani Backianathan, Deepak Thomas Abraham, Mazhuvanchary Jacob Paul, Raju Titus Chacko, Marie Therese Manipadam & Rekha Pai. (2024) Comparative analysis of mutational patterns in triple negative breast cancer before and after neoadjuvant chemotherapy in patients with residual disease. Gene 895, pages 147980.
Crossref
Crossref
Malihe Sadat Razavi, Alyeh Abdollahi, Atefeh Malek-Khatabi, Negin Mousavi Ejarestaghi, Ali Atashi, Nazanin Yousefi, Pedram Ebrahimnejad, Mohamed A. Elsawy & Rassoul Dinarvand. (2023) Recent advances in PLGA-based nanofibers as anticancer drug delivery systems. Journal of Drug Delivery Science and Technology 85, pages 104587.
Crossref
Crossref
Wenjing Hao, Jun Zhang, Yunxia Wang, Boyu Fang, Shasha Jin, Jing Yuan & Weimin Cai. (2023) Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis. Frontiers in Immunology 14.
Crossref
Crossref
Yichuan Jiang, Yueyao Jiang, Min Li & Qian Yu. (2023) Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?. Frontiers in Pharmacology 14.
Crossref
Crossref
Salma T. Rafik, Jayant S. Vaidya, Alexander J. MacRobert & Elnaz Yaghini. (2023) Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies. Journal of Clinical Medicine 12:7, pages 2648.
Crossref
Crossref
Jinu Mathew, Pallav Namdeo & Ashish Garg. 2023. Therapeutic Nanocarriers in Cancer Treatment: Challenges and Future Perspective. Therapeutic Nanocarriers in Cancer Treatment: Challenges and Future Perspective
349
381
.
Raiane Vieira Cardoso, Patricia Ribeiro Pereira, Cyntia Silva Freitas & Vania Margaret Flosi Paschoalin. (2022) Trends in Drug Delivery Systems for Natural Bioactive Molecules to Treat Health Disorders: The Importance of Nano-Liposomes. Pharmaceutics 14:12, pages 2808.
Crossref
Crossref
Mohammad Imran, Gowru Srivani & Ganji Seeta Rama Raju. 2022. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3
197
213
.
R.J.A. Vibhavari, Gautam Kumar, Vanishree Rao, Sri Pragnya Cheruku & Nitesh Kumar. 2021. Nano-Pharmacokinetics and Theranostics. Nano-Pharmacokinetics and Theranostics
117
152
.
Suzana Aulic, Domenico Marson, Erik Laurini, Maurizio Fermeglia & Sabrina Pricl. 2020. Nanomedicines for Breast Cancer Theranostics. Nanomedicines for Breast Cancer Theranostics
371
404
.
Sonali S. Rohiwal & Arpita Pandey Tiwari. 2020. Nanomedicines for Breast Cancer Theranostics. Nanomedicines for Breast Cancer Theranostics
331
349
.
Parth Patel & Yadvendrakumar Agrawal. (2019)
Preparation and
In-vitro
Evaluation of Levan Micelles: A Polyfructan Based Nano-carrier for Breast Cancer Targeted Delivery
. Drug Delivery Letters 9:2, pages 97-107.
Crossref
Crossref
Ji Eun Park, Joonyoung Park, Yearin Jun, Yunseok Oh, Gongmi Ryoo, Yoo-Seong Jeong, Hytham H. Gadalla, Jee Sun Min, Jung Hwan Jo, Myung Geun Song, Keon Wook Kang, Soo Kyung Bae, Yoon Yeo & Wooin Lee. (2019) Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. Journal of Controlled Release 302, pages 148-159.
Crossref
Crossref
Gopalakrishna Pillai. 2019. Applications of Targeted Nano Drugs and Delivery Systems. Applications of Targeted Nano Drugs and Delivery Systems
221
256
.
Mahdieh Moghiseh, Chiara Lowe, John G. Lewis, Dhiraj Kumar, Anthony Butler, Nigel Anderson & Aamir Raja. (2018)
Spectral Photon-Counting Molecular Imaging for Quantification of Monoclonal Antibody-Conjugated Gold Nanoparticles Targeted to Lymphoma and Breast Cancer: An
In Vitro
Study
. Contrast Media & Molecular Imaging 2018, pages 1-9.
Crossref
Crossref
Qingmei Li, Hong Zhang, Xiaoxue Zhu, Chengjiao Liu, Min Wu, Cuiyun Li, Xiaojiao Li, Lei Gao & Yanhua Ding. (2018) Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients. Frontiers in Pharmacology 9.
Crossref
Crossref
Firdos Khan, Sultan Akhtar, Sarah Almofty, Dana Almohazey & Munthar Alomari. (2018) FMSP-Nanoparticles Induced Cell Death on Human Breast Adenocarcinoma Cell Line (MCF-7 Cells): Morphometric Analysis. Biomolecules 8:2, pages 32.
Crossref
Crossref
Tahereh Fatemian & Ezharul Chowdhury. (2018) Cytotoxicity Enhancement in Breast Cancer Cells with Carbonate Apatite-Facilitated Intracellular Delivery of Anti-Cancer Drugs. Toxics 6:1, pages 12.
Crossref
Crossref
Mohammad M. Kamal & Sami Nazzal. (2018) Novel sulforaphane-enabled self-microemulsifying delivery systems (SFN-SMEDDS) of taxanes: Formulation development and in vitro cytotoxicity against breast cancer cells. International Journal of Pharmaceutics 536:1, pages 187-198.
Crossref
Crossref
F. Miglietta, M.V. Dieci, G. Griguolo, V. Guarneri & P.F. Conte. (2017) Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?. Cancer Treatment Reviews 60, pages 100-108.
Crossref
Crossref
Mark D. Vincent. (2017) Cancer: Towards a general theory of the target. BioEssays 39:9, pages 1700059.
Crossref
Crossref
Yihui Li, Hang Hu, Qing Zhou, Yanxiao Ao, Chen Xiao, Jiangling Wan, Ying Wan, Huibi Xu, Zifu Li & Xiangliang Yang. (2017) α-Amylase- and Redox-Responsive Nanoparticles for Tumor-Targeted Drug Delivery. ACS Applied Materials & Interfaces 9:22, pages 19215-19230.
Crossref
Crossref
Tatiana Andreani, Patrícia Severino, Luciana M. de Hollanda, Monica Vazzana, Selma B. Souto, Antonello Santini, Amélia M. Silva & Eliana B. Souto. 2017. Nanostructures for Cancer Therapy. Nanostructures for Cancer Therapy
241
260
.
Kewal K. JainKewal K. Jain. 2017. The Handbook of Nanomedicine. The Handbook of Nanomedicine
321
420
.
Zhi Li, Ao-Di Li, Lu Xu, De-Wei Bai, Ke-Zuo Hou, Hua-Chuan Zheng, Xiu-Juan Qu & Yun-Peng Liu. (2016) SPARC expression in gastric cancer predicts poor prognosis: Results from a clinical cohort, pooled analysis and GSEA assay. Oncotarget 7:43, pages 70211-70222.
Crossref
Crossref
Meng Gao, Dongjian Zhang, Qiaomei Jin, Cuihua Jiang, Cong Wang, Jindian Li, Fei Peng, Dejian Huang, Jian Zhang & Shaoli Song. (2016) Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model. Oncotarget 7:36, pages 58133-58141.
Crossref
Crossref
Cindy Neuzillet, Samy Babai, Emmanuelle Kempf, Géraldine Pujol, Benoît Rousseau, Hervé Le-Louët & Christophe Tournigand. (2016) Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion. Medicine 95:26, pages e4006.
Crossref
Crossref
XIAO-DONG JIAO, XIU LUO, WEN-XING QIN, LING-YAN YUAN & YUAN-SHENG ZANG. (2016) Paralytic ileus due to a novel anticancer drug, nab-paclitaxel: A case report. Molecular and Clinical Oncology 4:5, pages 824-826.
Crossref
Crossref
Wei Cui, Junbai Li & Gero Decher. (2015) Self‐Assembled Smart Nanocarriers for Targeted Drug Delivery. Advanced Materials 28:6, pages 1302-1311.
Crossref
Crossref
Pasupuleti Visweswara Rao, Devi Nallappan, Kondeti Madhavi, Shafiqur Rahman, Lim Jun Wei & Siew Hua Gan. (2016) Phytochemicals and Biogenic Metallic Nanoparticles as Anticancer Agents. Oxidative Medicine and Cellular Longevity 2016, pages 1-15.
Crossref
Crossref
Jiale Qin, Tzu-Yin Wang & Jürgen K. Willmann. 2016. Therapeutic Ultrasound. Therapeutic Ultrasound
263
291
.
Gregory Benedetto, C. Greer Vestal & Christine Richardson. (2015) Aptamer-Functionalized Nanoparticles as “Smart Bombs”: The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment. Targeted Oncology 10:4, pages 467-485.
Crossref
Crossref
AODI LI, XIUJUAN QU, ZHI LI, JINGLEI QU, NA SONG, YANJU MA & YUNPENG LIU. (2015) Secreted protein acidic and rich in cysteine antagonizes bufalin-induced apoptosis in gastric cancer cells. Molecular Medicine Reports 12:2, pages 2926-2932.
Crossref
Crossref
Sherif S Morgan, Raymond B Nagle & Lee D Cranmer. (2014) Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas. Clinical Sarcoma Research 4:1.
Crossref
Crossref
A. Viúdez, N. Ramírez, I. Hernández-García, F.L. Carvalho, R. Vera & M. Hidalgo. (2014) Nab-paclitaxel: A flattering facelift. Critical Reviews in Oncology/Hematology 92:3, pages 166-180.
Crossref
Crossref
Sebastian Strieth, Christoph Dunau, Uwe Michaelis, Lorenz Jäger, Donata Gellrich, Barbara Wollenberg & Marc Dellian. (2014) Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer. Head & Neck 36:7, pages 976-984.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2014. Applications of Biotechnology in Oncology. Applications of Biotechnology in Oncology
393
472
.
Nigel G. Anderson & Anthony P. Butler. (2014) Clinical applications of spectral molecular imaging: potential and challenges. Contrast Media & Molecular Imaging 9:1, pages 3-12.
Crossref
Crossref
Changsuk Lee, Su-Tang Lo, Jongdoo Lim, Viviana C. P. da Costa, Saleh Ramezani, Orhan K. Öz, Giovanni M. Pavan, Onofrio Annunziata, Xiankai Sun & Eric E. Simanek. (2013) Design, Synthesis and Biological Assessment of a Triazine Dendrimer with Approximately 16 Paclitaxel Groups and 8 PEG Groups. Molecular Pharmaceutics 10:12, pages 4452-4461.
Crossref
Crossref
Raphaelle Fanciullino, Joseph Ciccolini & Gérard Milano. (2013) Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs. Critical Reviews in Oncology/Hematology 88:3, pages 504-513.
Crossref
Crossref
Cindy Neuzillet, Annemilaï Tijeras-Raballand, Jérôme Cros, Sandrine Faivre, Pascal Hammel & Eric Raymond. (2013) Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer and Metastasis Reviews 32:3-4, pages 585-602.
Crossref
Crossref
James B DelehantyJoyce C Breger, Kelly Boeneman Gemmill, Michael H Stewart & Igor L Medintz. (2013) Controlling the actuation of therapeutic nanomaterials: enabling nanoparticle-mediated drug delivery. Therapeutic Delivery 4:11, pages 1411-1429.
Crossref
Crossref
Moom Sinn Aw, Mima Kurian & Dusan Losic. (2013) Polymeric Micelles for Multidrug Delivery and Combination Therapy. Chemistry – A European Journal 19:38, pages 12586-12601.
Crossref
Crossref
Michael E. Werner, Natalie D. Cummings, Manish Sethi, Edina C. Wang, Rohit Sukumar, Dominic T. Moore & Andrew Z. Wang. (2013) Preclinical Evaluation of Genexol-PM, a Nanoparticle Formulation of Paclitaxel, as a Novel Radiosensitizer for the Treatment of Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 86:3, pages 463-468.
Crossref
Crossref
Chris Oerlemans, Roel Deckers, Gert Storm, Wim E. Hennink & J. Frank W. Nijsen. (2013) Evidence for a new mechanism behind HIFU-triggered release from liposomes. Journal of Controlled Release 168:3, pages 327-333.
Crossref
Crossref
Shu-Ting Ren, Yi-Ran Liao, Xiao-Ning Kang, Yi-Ping Li, Hui Zhang, Hong Ai, Qiang Sun, Jing Jing, Xing-Hua Zhao, Li-Fang Tan, Xin-Liang Shen & Bing Wang. (2013) The Antitumor Effect of a New Docetaxel-Loaded Microbubble Combined with Low-Frequency Ultrasound In Vitro: Preparation and Parameter Analysis. Pharmaceutical Research 30:6, pages 1574-1585.
Crossref
Crossref
Demetria Ileana StrauchAlvaro Moreno-Aspitia. (2013) Overview of nanoparticle albumin-bound paclitaxel in metastatic breast cancer. Breast Cancer Management 2:3, pages 221-229.
Crossref
Crossref
Hatem A. Azim, Sandeep Singhal, Michail Ignatiadis, Christine Desmedt, Debora Fumagalli, Isabelle Veys, Denis Larsimont, Martine Piccart, Stefan Michiels & Christos Sotiriou. (2013) Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis. PLoS ONE 8:4, pages e62451.
Crossref
Crossref
Rebecca Senetta, Giulia Stella, Ernesto Pozzi, Niccolo Sturli, Daniela Massi & Paola Cassoni. (2013) Caveolin‐1 as a promoter of tumour spreading: when, how, where and why. Journal of Cellular and Molecular Medicine 17:3, pages 325-336.
Crossref
Crossref
G. von Minckwitz, M. Martin, G. Wilson, E. Alba, M. Schmidt, L. Biganzoli & A. Awada. (2013) Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Critical Reviews in Oncology/Hematology 85:3, pages 315-331.
Crossref
Crossref
Maria Vittoria Dieci, Valentina Guarneri & PierFranco Conte. (2012) The Future of Chemotherapy in the Era of Personalized Medicine. Current Breast Cancer Reports 5:1, pages 57-68.
Crossref
Crossref
James B Delehanty & Igor L Medintz. (2013) Controlled actuation of therapeutic nanoparticles: moving beyond passive delivery modalities. Therapeutic Delivery 4:2, pages 127-129.
Crossref
Crossref
Gopalakrishna Pillai & Maria L Ceballos-Coronel. (2013) Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. SAGE Open Medicine 1, pages 205031211351375.
Crossref
Crossref
Ruibing Wang, Paul S. Billone & Wayne M. Mullett. (2013) Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials. Journal of Nanomaterials 2013, pages 1-12.
Crossref
Crossref
Michele F. Oliveira, Pedro P. G. Guimarães, Alinne D. M. Gomes, Diego Suárez & Rubén D. Sinisterra. (2012) Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market. Journal of Chemical Biology 6:1, pages 7-23.
Crossref
Crossref
José M. Matés, Juan A. Segura, Francisco J. Alonso & Javier Márquez. (2012) Oxidative stress in apoptosis and cancer: an update. Archives of Toxicology 86:11, pages 1649-1665.
Crossref
Crossref
Xiao-Ming Zhu, Jing Yuan, Ken Cham-Fai Leung, Siu-Fung Lee, Kathy W. Y. Sham, Christopher H. K. Cheng, Doris W. T. Au, Gao-Jun Teng, Anil T. Ahuja & Yi-Xiang J. Wang. (2012) Hollow superparamagnetic iron oxide nanoshells as a hydrophobic anticancer drug carrier: intracelluar pH-dependent drug release and enhanced cytotoxicity. Nanoscale 4:18, pages 5744.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2012. The Handbook of Nanomedicine. The Handbook of Nanomedicine
271
341
.